After Yesterday's Rally of 2.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 13, 3:54PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.10 to a high of $51.37. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $50.77 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Teva Pharmaceutical Industries Set to Possibly Pullback After Yesterday's Rally of 2.42%
Comtex SmarTrend(R) - Tue May 13, 3:54PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.10 to a high of $51.37. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $50.77 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
M2 - Tue May 13, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs46lc/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. The pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. The two drug makers will combine and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline. Revenues of major pharma companies are broke out by these therapeutic areas in the report, Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023. Novartis has about 1/3 of its pharmaceutical revenues coming from oncology products. Thus it certainly makes sense to build that area, according to Kalorama's report. Novartis is currently number 2 in the world for cancer therapies behind Roche. The firm does not think that Novartis rises in market share from the deal, but it does believe it will certainly strengthen its position and maintain its wide distance from the 3rd competitor in the market. Although Kalorama also thinks the move benefits Glaxo Smith Kline, there could be less advantages for the company in the deal than for Novartis. Novartis will keep influenza vaccines, as part of the deal. This could work out to be highly beneficial, vaccines is a competitive area. The positions of companies do shift somewhat from year to year with vacillations in flu vaccines and other specific products, although for the past few years, Glaxo has led the market and Novartis has trailed at a distance. Furthermore, in pediatric vaccines GSK is also a major contributor and leader and solidifying this position is good but is not really helpful in the overall picture. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 estimates current sales for major pharmaceutical companies, breaks out revenue by therapeutic area and discusses general trends in the industry. Market watchers can use the report to understand developments in greater context than news media can provide. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 Top 25 Companies Mentioned - Abbvie, inc. - Actavis - Amgen, inc. - Astellas - Astra Zeneca plc - Baxter international - Bayer AG - Boehringer Ingelheim gmbh - Bristol-myers Squibb Company - Daiichi Sankyo - Eli Lilly and Company - Gilead Sciences - Glaxosmithkline PLC - Johnson & johnson - Merck & Co., inc. - Merck KGAA - Mylan - Novartis AG - Novo nordisk - Otsuka Pharmaceutical - Pfizer, inc. - Roche ltd. - Sanofi - Takeda Pharmaceutical co., LTD - Teva Pharmaceutical Industries, Ltd. For more information visit http://www.researchandmarkets.com/research/fs46lc/top_25
Teva Announces FDA Acceptance of sNDA Filing for Pediatric Indication for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol
Business Wire - Tue May 13, 7:31AM CDT
Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for a lower dose QNASL(R) (beclomethasone dipropionate) Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age. QNASL is a waterless intranasal corticosteroid spray currently available for the treatment of nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in patients 12 years of age and older.
Analyzing the Global Generics Industry 2014-2017
M2 - Mon May 12, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wcrhxw/analyzing_the) has announced the addition of the "Analyzing the Global Generics Industry 2014" report to their offering. This in-depth analysis of the global generics industry includes an industry definition, historical development of the industry, industry statistics, value and volume analysis, industry segmentation by geography, amongst others. We analyze the issue of patent expiries by therapeutic areas in details, looking at what the impact is on the generic drugs market. We also look at the industry structure, market entry as well as research & development in the industry. A Porter's Five Forces Strategy analysis of the global generics industry is also included in the report. The impact of regulatory framework on the generics industry in Europe, Japan and the United States is analyzed in the report, along with the trends and challenges in the global generics industry. We also look at the popularity of small molecule generic drugs as well as the growing focus on biosimilars. Challenge of life cycle management strategies are also looked at. Global generics industry strategies are analyzed as well. An important aspect of the global generics market is the pricing and reimbursement of generic drugs in major markets. We analyze the pricing and reimbursement in the key markets of Australia, Austria, China, Czech Republic, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Romania, Spain, Sweden, the UK and the United States. Key Topics Covered: A. Executive Summary B. Analyzing the Global Generics Industry C. Global Generics Industry: Porter's Five Forces Strategy Analysis D. Regulatory Framework & Impact on the Generics Industry E. Industry Trends & Challenges F. Industry Strategies G. Global Generics Industry: Analysis of Major Markets H. Pricing and Reimbursement of Generics: An Analysis by Major Markets I. Global Generics Industry Forecast J. Major Industry Players - Actavis - Apotex - Bayer AG - Biogaran S.A.S. - China Grand Pharmaceutical and Healthcare Holdings Limited - Daiichi Sankyo Co., Ltd. - Dr. Reddy's Laboratories Limited (DRL) - Esteve Group - Hospira Inc - Lupin - Mylan Inc. - Nichi-iko Pharmaceutical - Novartis AG - Par Pharmaceutical Companies, Inc. - Perrigo Company PLC - Ratiopharm Group - STADA Arzneimittel AG - Sandoz - Sanofi - Sawai Pharmaceutical Co., Ltd - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/wc...lyzing_the
Is This The Next Billion-Dollar Biotech Idea?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 9:30AM CDT
Developing a new drug costs hundreds of millions of dollars, but for every five drugs that reach the market, another 95 end up in the trash bin . That makes finding the next big thing in biotech particularly hit or miss. Frankly, the odds are...
Teva Pharmaceutical Industries Falls 1.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri May 09, 4:00PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $48.81 to a high of $50.13. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $49.29 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Teva Pharmaceutical Industries Set to Possibly Rebound After Yesterday's Selloff of 1.46%
Comtex SmarTrend(R) - Fri May 09, 4:00PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $48.81 to a high of $50.13. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $49.29 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Positive Medicines Board Opinion, Stock Price Updates, Drug Approval, Dividend Announcement, and Settlement of Claims - Analyst Notes on Allergan, Amgen, Teva, Lilly and Medtronic
PR Newswire - Fri May 09, 10:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Eli Lilly and Co. (NYSE: LLY) and Medtronic Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2265-100free.
Teva to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Fri May 09, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2014 Health Care Conference. Eyal Desheh, EVP & CFO will present on Tuesday, May 13, 2014 at 12:00 PM PT.
Teva Announces COPAXONE(R) Recognized as "Brand of the Year" by Pharmaceutical Executive Magazine
Business Wire - Thu May 08, 7:01AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE(R) (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.
Growth Hormone Deficiency - Pipeline Review, H1 2014: 24 Companies and 23 Drugs Profiled
M2 - Thu May 08, 3:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdp2w7/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - Access Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Ascendis Pharma A/S - Biogenomics - Bolder Biotechnology, Inc. - Braasch Biotech LLC - CJ CheilJedang Corp. - Critical Pharmaceuticals Limited - Delpor, Inc. - Emisphere Technologies, Inc. - Flamel Technologies S.A. - HanAll Biopharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - LG Life Sciences, Ltd. - OPKO Health, Inc. - Pfenex Inc. - Phage Pharmaceuticals, Inc. - PharmaEssentia Corporation - SynBio LLC - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Versartis, Inc. - XL-protein GmbH Drug Profiles: - somatropin SR - MOD-4023 - tesamorelin acetate - MOD-4023 - ARX-201 - ACP-001 - TV-1106 - SYN-20100504RU - somatropin - HL-032 - somatropin - ALRN-5281 - somatropin biobetter - CP-016 - CobOral hGH - BBT-031 - somatropin biosimilar - IBPB-003-HH - somatropin biosimilar - Vaccine For Growth Hormone Deficiencies - xl-020 - CJ-40002 - Pegylated Growth Hormone For more information visit http://www.researchandmarkets.com/research/jd...th_hormone
Is Abbott Laboratories Headed for a Breakup?
Dan Carroll, The Motley Fool - Motley Fool - Wed May 07, 5:30PM CDT
Dealing's back in style in health care's 2014. From major drugmakers looking to sell off slow-growth assets to big pharma's top names hunting for blockbuster acquisitions, the year's been home to no shortage of activity on the mergers and...
The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while OncoGenex Pharmaceuticals found out its...
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Narrower-than-Expected Loss at Momenta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 11:10AM CDT
Momenta Pharma (MNTA) reported 1Q14 net loss per share of 53 cents, narrower than the Zacks Consensus Estimate of a loss of 55 cents
Drug Addiction - Pipeline Review, H1 2014: 17 Company and 34 Drugs Profiled
M2 - Wed May 07, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp6lcx/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Addex Therapeutics - Alkermes Plc - Aphios Corporation - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - LondonPharma Ltd - Omeros Corporation - Rottapharm|Madaus - SK Biopharmaceuticals Co., Ltd. - Savant HWP, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles: - nepicastat hydrochloride - ibudilast - buprenorphine hydrochloride - SKL-N05 - Butyrylcholinesterase - candesartan cilexetil - baclofen ER - ketamine hydrochloride - (oxazepam metyrapone) - (samidorphan buprenorphine hydrochloride) - LT-22 - ASB - methadone - dronabinol - ADX-88178 - ADX-71441 - OMS-527 - Vaccine For Cocaine Addiction - Cocaine Addiction Vaccine - MH-6 Vaccine - MH-2 [R] Vaccine - Ibogaine Analog - 5HT2 Modulators for CNS and Metabolic Disorders - CM-1212 - methoxycoronaridine - ICKLH-SMO9 Vaccine - N-acetylcystein MGluR5 Antagonist - CR-5542 Series - Small Molecules to Inhibit DAT and SERT for CNS Disorders - Triazole Compounds For more information visit http://www.researchandmarkets.com/research/sp..._addiction
Huntington's Disease - Pipeline Review, H1 2014: 50 Company and 93 Drug Profiles
M2 - Wed May 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bgc4/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - GAcadia Pharmaceuticals Inc. - Accera, Inc. - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Aniona ApS - Auspex Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Centre de Regulacio Genomica - Chronos Therapeutics Limited - Cortex Pharmaceuticals, Inc. - CrystalGenomics, Inc. - EncephRx, Inc. - Evotec AG - GW Pharmaceuticals plc - Galenea Corp. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - Treventis Corporation - Trophos SA - UniQure BV - Valens Therapeutics, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - VivaCell Biotechnology Espana S.L. - Vybion, Inc. - Wellstat Therapeutics Corporation - enzyme Corporation - iPierian, Inc Drug Profiles: - pridopidine - SD-809 ER - Coenzyme Q10 - cysteamine DR - PF-02545920 - nabiximols - selisistat - PBT-2 - Epigallocatechin Gallate - BN-82451 - SOM-3355 - OMS-824 - SRX-251 - SRX-246 - SUVN-502 - GSK-356278 - uridine triacetate - Lithium citrate - ALN-HTT - CERE-120 - INDUS-815C - AC-0523 - Xpro-1595 - AN-726 - CX-929 - VAR-10300 - AMT-090 - noscapine - NsG-33 - MTP-131 For more information visit http://www.researchandmarkets.com/research/v2...untingtons
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma
Substance (Drug) Abuse - Pipeline Review, H1 2014: Includes 10 Company and 31 Drug Profiles
M2 - Wed May 07, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rb6x74/substance_drug) has announced the addition of the "Substance (Drug) Abuse - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Addex Therapeutics - Adial Pharmaceuticals, LLC - AllTranz, Inc. - Foresee Pharmaceuticals, LLC - Grunenthal GmbH - InterveXion Therapeutics LLC - Reckitt Benckiser Pharmaceutical, Inc. - Rottapharm|Madaus - Snowdon Inc. - Teva Pharmaceutical Industries Limited Drug Profiles: - acetylcysteine - lithium carbonate - acetylcysteine - Icariin - nabilone - neboglamine - aripiprazole - doxazosin mesylate - lisdexamfetamine dimesylate - naltrexone - carvedilol phosphate - acetylcysteine - buspirone hydrochloride - RBP-8000 - hydrocodone bitartrate ER - aripiprazole - ondansetron - Ch-mAb7F9 - L-Tetrahydropalmatine - lisdexamfetamine dimesylate - ADX-88178 - ADX-71441 - Program For Neurological Disorders - ADX-71743 - Vaccine For Drug Abuse - Mutated CocE Polypeptides - Anti-METH Vaccine - Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - VU-0463841 For more information visit http://www.researchandmarkets.com/research/rb...tance_drug